Pulmonx Corporation — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 15, 2021. Pulmonx is a commercial-stage medical technology company focused on severe emphysema. Its solution combines the Zephyr Endobronchial Valve, Chartis assessment system and StratX CT-analysis platform. Zephyr Valve sales and delivery catheters generated most revenue; StratX did not generate independent revenue.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $32.7 million | $32.6 million |
| Gross profit / gross margin | $21.2 million / 64.8% | $22.4 million / 68.8% |
| Operating expenses | $53.5 million | $40.3 million |
| Operating loss | $32.3 million | $17.8 million |
| Net loss | $32.2 million | $20.7 million |
| Cash used in operating activities | $30.6 million | $20.8 million |
- At year-end, cash and cash equivalents were $231.6 million, working capital was $237.5 million, and accumulated deficit was $242.7 million.
- Reported debt carrying amounts were $16.8 million for the CIBC term loan and $0.6 million for the Swiss credit agreement. The CIBC loan is secured by substantially all company assets. The 2020 convertible notes converted to common stock at the October IPO.
- The October 2020 IPO generated approximately $201.4 million in net proceeds. Financing cash flow was $234.8 million; investing cash flow was positive $12.7 million, primarily from investment maturities.
- There were no dividends. Management said cash on hand was expected to fund planned operations for at least 12 months from the financial statements’ issuance.
Material changes and quarterly performance
- Annual revenue was nearly unchanged, but U.S. revenue rose to $16.2 million from $10.7 million while international revenue fell to $16.5 million from $21.9 million. International markets represented 50.5% of revenue, down from 67.2% in 2019.
- COVID-19 disrupted procedures and reduced international sales. U.S. gains largely offset the international decline. Revenue recovered after the second-quarter trough, then weakened in November and December.
- Fourth-quarter 2020 revenue was $9.8 million versus $10.6 million in Q3 2020 and $10.3 million in Q4 2019. Q4 net loss was $9.3 million, compared with $3.9 million in Q3 2020 and $4.7 million in Q4 2019.
- Gross margin declined year over year, which management attributed mainly to lower manufacturing utilization during the pandemic and increased manufacturing costs and infrastructure investment.
- Operating expenses increased 33%, led by higher selling, general and administrative costs, including sales-force expansion, stock-based compensation, public-company costs and a $3.0 million write-off of deferred IPO costs after an earlier offering registration was withdrawn. Other income included favorable fair-value adjustments associated with the IPO and convertible-note derivatives.
Outlook, risks and contingencies
- Management anticipated improving 2021 sales if vaccine efficacy, availability and delivery and broader responses to the pandemic supported recovery. It cautioned that a renewed outbreak, fewer deferred procedures, or limited hospital capacity could impede recovery. The filing provides no quantified revenue or earnings guidance.
- The company expects continued losses and substantial investment in sales and marketing, R&D, clinical work and commercialization. AeriSeal received FDA Breakthrough Device designation in December 2020, but remains in early development; Pulmonx intended to submit an IDE to begin a clinical trial.
- Zephyr Valve use carries material safety risks. In clinical trials, pneumothorax occurred in 18%–34% of treated patients. In the LIBERATE study, four treatment-period deaths occurred in the valve group and none in the control group; investigators considered three definitely and one probably related to treatment. Current practice is to monitor patients in hospital for at least three nights.
- Commercial success depends on hospital, physician and patient adoption and adequate reimbursement. Medicare coverage is case-by-case, and some commercial plans lack positive coverage policies. The company relies on a single principal product and has limited long-term safety and effectiveness data; five-year LIBERATE extension results were not expected until 2023.
- Additional risks include COVID-related procedure disruption, competition, reliance on single-source suppliers and a single manufacturing site, regulatory compliance, intellectual property, foreign currency and cybersecurity. The CIBC facility contains revenue and liquidity covenants; the company reported compliance at year-end after extending certain covenant compliance dates to June 30, 2021.
- A former international distributor lawsuit alleges unfair competition and breach of exclusive distribution rights. The company said it did not expect the matter to have a material effect; the filing also states there were no material legal proceedings.
Most important facts for investors to verify
- Whether procedure volumes and revenue recovered after the late-2020 and early-2021 COVID-19 disruption, and whether quarterly growth is driven by sustainable demand rather than a temporary backlog.
- Whether gross margin stabilizes or improves as manufacturing utilization rises, and whether operating expenses and cash burn remain aligned with revenue growth.
- Current unrestricted liquidity, debt balances, covenant compliance and availability of additional CIBC or convertible-note borrowing capacity.
- Coverage-policy developments, prior-authorization outcomes and reimbursement adequacy across Medicare and commercial payors.
- Post-market safety findings, pneumothorax rates and progress of the LIBERATE extension study and AeriSeal clinical plans.
- Supplier continuity and manufacturing capacity, as well as the outcome and potential financial exposure of the distributor dispute.